Journal Article (Review Article)

DKFZ-2018-02257

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Perspectives of immunotherapy in isocitrate dehydrogenase-mutant gliomas.

Friedrich, M. (First author)DKFZ* ; Bunse, L.DKFZ* ; Wick, W.DKFZ* ; Platten, M. (Last author)DKFZ*

2018
Ovid [S.l.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1097/CCO.0000000000000478

Abstract: The present review introduces recent progress in eliciting the role of mutant isocitrate dehydrogenase (IDH) in gliomas, especially regarding its mode of action as a modulator of antitumor immune response, and provides rationales for targeting mutant IDH in glioma immunotherapy. Both the development of small molecule inhibitors repressing the enzymatic activity of mutant IDH and novel, mechanism-led combination immunotherapies are discussed.Since the discovery of highly frequent IDH mutations in low-grade gliomas and nonsolid malignancies, its tumor cell-intrinsic effects have been intensively investigated. Tumor cells expressing mutant IDH display profound alterations of redox control capacity, phospholipid profile, and ATP supply. Recent findings suggest that IDH mutations - via intricate, yet druggable pathways - cause immunological alterations, highlighting the importance of oncogenic drivers as modulators of antitumor immunity and targets for immunotherapy.Mutant IDH is not only a disease-defining biomarker and oncogenic driver in glioma, but is also a neoantigen and a regulator of glioma immune evasion. Effective and specific strategies targeting the immunomodulatory properties of mutant IDH may complement current (immuno-)therapeutic strategies and approved antiglioma treatments to improve outcome.

---

Contributing Institute(s):

1. Neuroimmunologie und Hirntumorimmunologie (G160)
2. KKE Neuroonkologie (G370)
3. DKTK Heidelberg (L101)

Research Program(s):

1. 317 - Translational cancer research (POF3-317) (POF3-317)

Appears in the scientific report 2018

---

Database coverage:
; Allianz-Lizenz ; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; IF < 5 ; IF < 5 ; JCR ; NCBI Molecular Biology Database ; Nationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---